Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

71.19 -1.22 (-1.68%)
Streaming Delayed Price Updated: 3:36 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,949,980
Open 71.95
Bid (Size) 71.19 (2)
Ask (Size) 71.20 (2)
Prev. Close 72.41
Today's Range 70.78 - 72.29
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.21%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
Via Benzinga

Performance

YTD
-14.47%
-14.47%
1 Month
+0.66%
+0.66%
3 Month
+6.34%
+6.34%
6 Month
-9.22%
-9.22%
1 Year
-8.32%
-8.32%

More News

Read More
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
Via Talk Markets
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Via Benzinga
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
Check Out What Whales Are Doing With GILD
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
Via The Motley Fool
Topics ETFs
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Via InvestorPlace
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
Via The Motley Fool
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,400 Today
Via Benzinga
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Via InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Is Iovance Biotherapeutics a Millionaire Maker?
Via The Motley Fool
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Via InvestorPlace
3 Underappreciated Stocks About to Break Their Chains
Via InvestorPlace
Oil Declines Amid Prospects Of An Agreement Between Israel And Hamas. Powell Will Address The Us Congress Today
Via Talk Markets
Topics Stocks
Exposures US Equities
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Amgen, Inc. Dividend Stock Analysis
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.